Atrium Health Sanger Heart & Vascular Institute

🚨 Cancer patients are showing up in every cardiology clinic - are you ready? 🧠 Join us for our 2nd Annual Cardio-Oncology Symposium! #cardioonc 🌟 National Experts + Complex Cases 🗓️ Sat Oct 11th 8am-4pm (hybrid) ✅ CME/MOC+APP/Pharm/RN (CE) 👉REGISTER: site.pheedloop.com/event/SHVICard…

Great showing by cardiologists & surgeons from Atrium Health Sanger Heart & Vascular Institute at the @sacsconference. Our teams highlighted leading-edge advances in cardiovascular care—from heart failure and structural heart to transplant and #ACHD. Great work team!

📈 What’s next in DCD heart transplant? 💡 New perfusion tech (XVIVO, SherpaPak) 🧠 Ongoing research to address brain reperfusion ethics 💵 Sustainability tied to cost, logistics, & access If ethical concerns resolve, NRP may become dominant. #CardioTwitter #Transplant

🚨 Key DCD insights from #SACS2025: 🫀 DPP reduces cold ischemic time but has higher rates of PGD 🫀 NRP improves functional assessment & organ yield, with cost benefits—but raises ethical concerns Survival data is strong for both. Future may hinge on standardization + tech

New era in heart transplantation. Donation after circulatory death (DCD) is expanding donor pool—w/two primary techniques emerging: 🔵 Direct Procurement & Perfusion (DPP) 🟡 Thoracoabdominal Normothermic Regional Perfusion (TA-NRP) Each w/ pros, cons, and ethical complexity.

Timing matters. From arrhythmias to heart failure, cardio complications can hit during and after pregnancy. ACHD experts at #SACS dissect when and how to intervene—and what OB teams must know to keep patients safe. #ACHD #CardioOB

Cardio-OB is high-stakes teamwork. At today’s #SACS ACHD Symposium, Dr. Anthony Gregg dives into what OB teams need to know—and fear—when caring for pregnant patients with congenital heart disease. Cross-specialty collaboration is critical. #ACHD #CardioOB

Huge congratulations to our team for leading the 5th Annual ACHD Symposium at #SACS! 👏 From complex case-based discussions to advancing care for adults with congenital heart disease, this collaborative effort is improving outcomes across the country. #ACHD #AdvocateHealth

💡 Exercise & aortopathy aren’t mutually exclusive. Benefits include ↓ BP, improved endothelial function, autonomic regulation. But guidance matters—especially for those with genetic risk. 📝 Define normal vs abnormal. Prescribe, don’t prohibit

Evaluation must go beyond measurements: ✔️ Genetic testing (e.g., Marfan, Loeys-Dietz) ✔️ Family + MSK history ✔️ Aortic valve morphology ✔️ Imaging accuracy (echo, CT, MR) 50% of dissections <40 y/o are tied to Marfan syndrome. Don’t miss the diagnosis. #AorticHealth #Imaging

Sports cardiology @sacsconference 35-year-old CrossFit athlete was referred for aortic root enlargement. Imaging showed progressive dilation (~41 mm, Z-score 3.38). No symptoms. Family history notable for sudden death in father. Is this athletic remodeling—or early aortopathy?

👩‍⚕️ Implementation matters. Nurse-led CMI clinics monitor echo & adjust dosing to keep patients stable. 🩺 Decision-making should be shared, tailored, and guided by local expertise. CMIs, surgery, or both—right therapy depends on residual symptoms. #HCMCare #TeamBasedCare

📊 Long-term mavacamten data shows sustained reductions in LVOT gradient and NYHA class improvement. While CMIs can transiently lower LVEF, heart failure remains rare with proper monitoring. Safety and efficacy hold strong over 3+ years. #HeartFailure

@sacsconference 🧬 Cardiac Myosin Inhibitors (CMIs) like mavacamten (FDA-approved) and aficamten (in trials) are reshaping treatment for obstructive HCM. They improve symptoms, exercise tolerance, and quality of life—while reducing the need for invasive procedures. #HCM

Atrium Health and Advocate Health are already putting this into practice — using these therapies not only to reduce readmissions, but to help patients feel better, sooner. It's not just about survival — it's about quality of life. #HeartFailure

They're evidence-based strategies for weight loss, CV protection, and now—perioperative optimization. The @ACCinTouch now officially recommends GLP-1 and SGLT2i therapies to improve cardiovascular outcomes in people with obesity and heart failure.

At #SACS2025 We dive into the perioperative implications of SGLT2i and GLP-1/GIP therapies — now essential tools in managing surgical risk for patients with heart failure and diabetes. SGLT2 inhibitors like Jardiance and GLP-1s like Ozempic & Wegovy are more than glucose meds.

New research shows non-atriotomy surgical ablation + LAAO drastically reduces post-op Afib after CABG. A 41% reduction vs. 4.7% in standard procedures. Game-changer. #SACS2025 #CardiacSurgery

Afib is linked to a 5x increased risk of stroke, 5x greater risk of heart failure, and 46% higher risk of death. The burden isn’t just clinical—it’s emotional, cognitive, and economic. $26B annually in U.S. healthcare costs. #SACS2025 #AFib

Atrial fibrillation affects 37+ million people worldwide—and it’s far more dangerous than many realize. At #SACS2025, we’re learning that more than half of Afib patients over 65 won’t survive five years post-diagnosis. Let that sink in. #AFibAwareness